



## Oncologist-to-Oncologist Review Yields \$178K in Plan Savings

*for a single encounter*

### Janice\* | 67 years old

MSS (microsatellite stable), BRCA negative, metastatic pancreatic cancer with disease progression to the liver following surgery and adjuvant gemcitabine plus capecitabine chemotherapy. ECOG=1.

*\*Not patient's real name*

Our oncology expertise helps you reduce costs and improve outcomes while enhancing provider and member experience. Contact your OncoHealth sales lead or email [inquiries@oncohealth.us](mailto:inquiries@oncohealth.us) for more information.

OncoHealth's OneUM™ is the only digital prior authorization platform built exclusively for oncology. It provides regimen-level review to balance safety, efficacy, and cost containment. This case illustrates how real-world data and oncologist-to-oncologist consultation resulted in both savings and improved quality of care.

### Treating Oncologist Request

- **Nivolumab (Opdivo) + Ipilimumab (Yervoy)**
- **3-month cost = \$178,932**

### OncoHealth Clinical Review

- Drugs are off-label, off-evidence
- Patient is not MSI-High so pembrolizumab is not an option
- Clinical trial enrollment is recommended
- Standard of care chemotherapy options remained

### Oncologist-to-Oncologist Peer Review

- Consider standard of care FOLFIRINOX (Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan) as an alternative
- FOLFIRINOX has a survival advantage in this setting
- Or: Clinical Trial

### Results: 3-Month Drug Cost Savings to Health Plan: ~\$177,943

- Therapy changed to **FOLFIRINOX**
- Patient received standard of care regimen with proven efficacy, improved quality of care, and reduced financial toxicity – hopefully adding months to the patient's life as compared to therapy with no survival advantage